Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSG4112 in Overweight and Obese Patients
NCT05197556Phase 2Completed
- Sponsor
- Glaceum
- Start
- Feb 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vutiglabridin in obesity (4 arms), sponsored by Glaceum. Primary endpoints: Change in Body Weight at 12 weeks and Evaluation of Safety and Tolerability by Adverse Event Monitoring at 16 weeks. Started Feb 2022; status: completed.
02
Drugs
vutiglabridin
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05197556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05197556.